Improved Bicyclic Pyrrolidine Analogues Inhibit Toxoplasma gondii Growth In Vitro and Cure Infection In Vivo
Year: 2025
Type: article
Abstract: Inhibition of phenylalanine tRNA synthetase (PheRS) by bicyclic pyrrolidines provides a potent and specific inhibition of parasite growth. Herein, we describe novel bicyclic pyrrolidines designed to explore structure–activity relationships with Toxoplasma gondii vs human PheRS. Modification of the biaryl alkyne extension, which fits into the phenylalanine-binding site, showed a strong preference for ortho hydroxyl addition over meta and para. Further addition of N to both the proximal and distal phenyl rings of the biaryl alkyne and to the methoxyphenyl urea moiety, which fits into a unique auxiliary site present in the parasite enzyme, identified compounds with reduced plasma protein binding and lower hERG activity. Finally, we identified a potent lead with improved pharmacokinetics, extended plasma exposure, central nervous system penetration, and low-dose cure of acute infection in mouse. Collectively, these findings advance new candidates for the treatment of toxoplasmosis based on selective and potent inhibitors of parasite PheRS.
Source: Journal of Medicinal Chemistry
Authors: Taher Uddin, Han Xie, Payal Mittal, Chloe C. Ence, Shrushti Patil, Amit Sharma, Bruno Melillo, Arnab K. Chatterjee, L. David Sibley
Institutions: Washington University in St. Louis, California Institute for Biomedical Research, Indian Council of Medical Research, International Centre for Genetic Engineering and Biotechnology, International Centre for Genetic Engineering and Biotechnology, National Institute of Malaria Research, International Centre for Genetic Engineering and Biotechnology, Academy of Scientific and Innovative Research, Broad Institute, Scripps Research Institute
Language: English
Subfield: Parasitology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: G2447883907, G3918329373
OpenAlex ID: W4413051276
